{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:38:57Z","timestamp":1789911537280,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40265-016-0620-1","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T08:18:53Z","timestamp":1469002733000},"page":"1313-1318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Pitolisant: First Global Approval"],"prefix":"10.1007","volume":"76","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,20]]},"reference":[{"issue":"4","key":"620_CR1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","volume":"163","author":"JC Schwartz","year":"2011","unstructured":"Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713\u201321.","journal-title":"Br J Pharmacol."},{"issue":"9560","key":"620_CR2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","volume":"369","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499\u2013511.","journal-title":"Lancet."},{"issue":"9197","key":"620_CR3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39\u201340.","journal-title":"Lancet."},{"key":"620_CR4","unstructured":"European Medicines Agency. Wakix (pitolisant): summary of product characteristics. 2016. http:\/\/www.ema.europe.eu . Accessed 13 Jun 2016."},{"key":"620_CR5","unstructured":"French National Agency for Medicines and Health Products Safety. WAKIX 20\u00a0mg, comprim\u00e9 pellicul\u00e9 quadris\u00e9cable [media release]. 2014. http:\/\/ansm.sante.fr ."},{"key":"620_CR6","unstructured":"European Medicines Agency. Public summary of positive opinion for orphan designation of 1-{3-[3-(4 chlorophenyl)propoxy]propyl}piperidine, hydrochloride for the treatment of narcolepsy. 2010. http:\/\/www.ema.europa.eu . Accessed 14 Jun 2016."},{"key":"620_CR7","unstructured":"Search orphan drug designations and approvals [database on the Internet] [cited 29 Jan]. Available from: http:\/\/www.fda.gov ."},{"issue":"Suppl 1","key":"620_CR8","first-page":"S8","volume":"63","author":"JC Schwartz","year":"2014","unstructured":"Schwartz JC. Clinical trials with pitolisant (WAKIX) a wake-promoting H3-receptor inverse agonist [abstract no. L1]. Inflamm Res. 2014;63(Suppl 1):S8.","journal-title":"Inflamm Res."},{"key":"620_CR9","doi-asserted-by":"publisher","unstructured":"Collart Dutilleul P, Ryvlin P, Kahane P, et al. Exploratory phase II trial to evaluate the safety and the antiepileptic effect of eitolisant (BF2.649) in refractory partial seizures, given as adjunctive treatment during 3\u00a0months. Clin Neuropharmacol. 2016. doi: 10.1097\/WNF.0000000000000159 .","DOI":"10.1097\/WNF.0000000000000159"},{"key":"620_CR10","unstructured":"Alium Medical Limited. Alium Medical announces exclusive distribution rights for narcolepsy innovative product Wakix (pitolisant) [media release]. 22 Sep 2014. http:\/\/www.samedanltd.com ."},{"issue":"1","key":"620_CR11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.106.111039","volume":"320","author":"X Ligneau","year":"2007","unstructured":"Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther. 2007;320(1):365\u201375.","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"620_CR12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","volume":"30","author":"JS Lin","year":"2008","unstructured":"Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin\u2212\/\u2212 mice and patients. Neurobiol Dis. 2008;30(1):74\u201383.","journal-title":"Neurobiol Dis."},{"issue":"3","key":"620_CR13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/bph.12149","volume":"169","author":"M Uguen","year":"2013","unstructured":"Uguen M, Perrin D, Belliard S, et al. Preclinical evaluation of the abuse potential of pitolisant, a histamine H3 receptor inverse agonist\/antagonist compared with modafinil. Br J Pharmacol. 2013;169(3):632\u201344.","journal-title":"Br J Pharmacol."},{"issue":"6","key":"620_CR14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.sleep.2014.01.021","volume":"15","author":"S Leu-Semenescu","year":"2014","unstructured":"Leu-Semenescu S, Nittur N, Golmard JL, et al. Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. Sleep Med. 2014;15(6):681\u20137.","journal-title":"Sleep Med."},{"issue":"11","key":"620_CR15","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"12","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068\u201375.","journal-title":"Lancet Neurol."},{"issue":"2","key":"620_CR16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WNF.0b013e318246879d","volume":"35","author":"C Inocente","year":"2012","unstructured":"Inocente C, Arnulf I, Bastuji H, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012;35(2):55\u201360.","journal-title":"Clin Neuropharmacol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0620-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0620-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0620-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:49:17Z","timestamp":1498315757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0620-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,20]]},"references-count":16,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0620-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,20]]}}}